This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Milk alkali syndrome

Authoring team

Milk-alkali syndrome is characterised by hypercalcaemia, alkalosis and renal failure. It results from excessive ingestion of calcium and absorbable antacids such as milk or calcium carbonate. The frequency of this syndrome has decreased since the availability of H2 receptor antagonists (and then proton pump inhibitors) for the treatment of peptic ulcer disease.

There seems a genetic factor in the development of this syndrome because many patients are treated with calcium carbonate without developing the syndrome.

There is a cycle of mild hypercalcaemia which leads to bicarbonate retention which turn in causes alkalosis and subsequent renal calcium retention. This sequence of events results in severe hypercalcaemia. This cycle perpetuates hypercalcaemia and alkalosis as long as calcium and absorbable alkali are ingested.

Features of this syndrome include weakness, myalgia, irritability and apathy. Impairment of renal function, hypercalcaemia and alkalosis all reverse rapidly upon stopping the intake of calcium and alkali.


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.